{"id":"NCT01158157","sponsor":"Emergent BioSolutions","briefTitle":"VA-006 Vaccinia Vaccine (ACAM2000) for the Production of VIGIV","officialTitle":"Vaccinia Vaccine (ACAM2000) for the Production of Vaccinia Immune Globulin Intravenous (VIGIV)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-09-13","primaryCompletion":"2012-02-14","completion":"2012-02-14","firstPosted":"2010-07-08","resultsPosted":"2019-03-26","lastUpdate":"2024-03-18"},"enrollment":25,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Smallpox Vaccine Adverse Reaction"],"interventions":[{"type":"BIOLOGICAL","name":"ACAM2000","otherNames":[]}],"arms":[{"label":"Vaccination","type":"OTHER"}],"summary":"The purpose of this study is to vaccinate plasma donors with ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacturing of Vaccinia Immune Globulin Intravenous (VIGIV).","primaryOutcome":{"measure":"Percent of Participants With Adverse Events Related to ACAM2000 Vaccine Administration","timeFrame":"Days 0 to 90 post-vaccination","effectByArm":[{"arm":"ACAM200 Vaccination Dose","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":7,"exclusionCount":9},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["10458959"],"seeAlso":["http://whqlibdoc.who.int/wer/WHO_WER_1980/WER1980_55_145-152%20(N%C2%B020).pdf","http://www.cdc.gov/mmwr/","http://www.cdc.gov/mmwr/","http://www.cdc.gov/mmwr/","http://www.cdc.gov/mmwr/"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":25},"commonTop":["Vaccination complication","Headache","Injection site scab"]}}